期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

液体肿瘤生物指标检测对乳腺癌患者的临床价值 被引量：11

The clinical value of liquid tumor biomarker detection for breast cancer
下载PDF
导出
摘要 循环肿瘤标志物在乳腺癌中的应用受到越来越多的关注,研究水平已从蛋白质水平深入到基因水平,相应的检测指标则从传统的肿瘤标志物扩展到相对特异的HER-2蛋白质细胞外段、循环肿瘤细胞、循环肿瘤DNA及循环RNA等。作为"液体检测",循环肿瘤标志物的检测因其实时动态、操作简便、可重复性好等优势,被广泛应用于协助早期诊断、判断预后、预测疗效、监测疾病复发及病情变化等方面。对循环肿瘤标志物的深入研究,有助于实现患者的个体化治疗。 Circulating tumor markers have been paid more attention in the application of the treatment for breast cancer, the level of which has extended from protein to gene, including traditional tumor markers, HER-2 extracellular domain, circulating tumor cells, circulating tumor DNA （ctDNA）, circulating RNA （ctRNA） and so on. As “liquid detection”, the detection of circulating tumor markers with real-time dynamic, easy operation, good reproducibility and other advantages are widely used in aiding early diagnosis, determining prognosis, prospectively predicting response or resistance to speciifc therapies, surveillance after primary surgery, and monitoring therapy in patients with advanced disease, The further study of circulating tumor markers may contribute to patient’s individual treatment.
作者 周金妹 江泽飞
机构地区 军事医学科学院附属医院乳腺肿瘤内科
出处 《中国癌症杂志》 CAS CSCD 北大核心 2014年第8期636-640,共5页 China Oncology
关键词 乳腺癌 CA15—3 CEA 蛋白质细胞外段 循环肿瘤细胞 循环肿瘤DNA 循环肿瘤RNA Breast cancer Carcino-embryonic antigen Extracellular domain Circulating tumor cells Circulating tumor DNA Circulating tumor RNA
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献41

  • 1LEE J S, PARK S, PARK J M, et al. Elevated levels of preoperative CA 15-3 and CEA serum levels" have independently poor prognostic significance in breast cancer [ J ] . Ann Oneol, 2013, 24(5): 1225-1231.
  • 2BAHRAMI A, MORTAZAVIZADEH M R, YAZDI M F, et al. Serial tumor markers serum earcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients [ J ] . East Mediterr Health J, 2012, 18(10): 1055-1059.
  • 3NICOLINI A, CARPI A, MICHELASSI C, et al. "Tumour marker guided" salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study [ J ] . Biomed Pharmacother, 2003, 57(10): 452-459.
  • 4STURGEON C M, DUFFY M J, STENMAN U H, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers [ J ] . Clin Chem, 2008, 54(12): 11-79.
  • 5PEDERSEN A C, SORENSEN P D, JACOBSEN E H, et al. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer [ J ] . Clin Chem, 2013, 51(7): 1511-1519.
  • 6ALI S M, CARNEY W P, ESTEVA F J, et al. Serum HER-2/ neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer [ J ] . Cancer, 2008, 113(6): 1294-1301.
  • 7ESTEVA F J, CHELI C D, FRITSCHE H, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies [ J ] . Breast Cancer Res, 2005, 7(4): 436-443.
  • 8FORNIER M N, SEIDMAN A D, SCHWARTZ M K, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by try andfluorescence in situ hybridization and with response rate [ J ] . Ann Oncol, 2005, 16(2): 234-239.
  • 9LIPTON A, LEITZEL K, ALI S M, et al. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy [ J ] . Cancer, 2011, 117(21): 5013-5020.
  • 10ARDAVANIS A, KOUNTOURAKIS P, KYRIAKOU F, et al. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/ HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer [ J ] . Oncologist, 2008, 13(4): 361- 369.

同被引文献119

  • 1王蒙,杨超,刘运江.原发性乳腺癌患者外周血循环肿瘤细胞及肿瘤干细胞的检测及临床意义[J].中国老年学杂志,2014,34(3):623-625. 被引量：5
  • 2Gradishar WJ, Anderson BO, Blair SL, et al. Breast cancer version 3. 2014 [ J ]. J Natl Compr Cane Netw,2014,12 (4) : 542 - 590.
  • 3Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen Internation',d Expert Consensus on the primary therapy of early breast cancer 2013 [ J ]. Ann Oneol, 2013, 24 (9) :2206 - 2223.
  • 4Bian L, Wang T, Zhang S, et al. Trastuzumab plus capecit- abine vs. lapatinib plus capecitabine in patients with trastu- zumab resistance and taxane - pretreated metastatic breastcancer[ J ]. Tumor Bio1,2013,34 (5) :3153 - 3158.
  • 5Hynes NE,Lane HA. ERBB receptors and cancer:the com- plexity of targeted inhibitors [ J ]. Nat Rev Cancer, 2005,5 (5) :341 -354.
  • 6Hegde PS, Rusnak D, Bertiaux M, et al. Delineation of mo- lecular mechanisms of sensitivity to lapatinib in breast canc- er cell lines using globa/ gene expression profiles [ J ]. Mol Cancer Ther,2007,6(5 ) : 1629 - 1640.
  • 7Rusnak DW, Lackey K, Affleek K, et al. The effects of the novel,reversible epidermal growth factor receptor/ErbB -2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor - derived cell lines in vitro and in rive [ J ]. Mol Cancer Ther,2001,1 ( 2): 85 - 94.
  • 8Bence AK, Anderson EB, Halepota MA, et al. Phase I phar- macokinetic studies evaluating single and multiple doses of oral GW572016,a dual EGFR- ErbB2 inhibitor, in healthy subjects [ J ]. Invest New Drug, 2005,23 ( 1 ) : 39 - 49.
  • 9Burris HA,Hurwitz HI,Dees EC,et al. Phase I safety,phar- macokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas [ J ]. J Clin Oncol,2005, 23(23) :5305 -5313.
  • 10Burstein H J, Storniolo AM, Franco S, et al. A phase lI study of lapatinibmonotherapy in chemotherpy - refractory HER2 - positive and HER2 - negativeadvancedmetastatic breast cancer [ J ]. Ann Oncol, 2008,19 ( 6 ) : 1068 - 1074.

引证文献11

二级引证文献31

中国癌症杂志
2014年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部